2 insiders bought €43k of shares over the last 90 days, the latest by 강일모, filed 16 Sept 2026.
KMPHARMACEUTICAL Co.,Ltd.: what insiders have been doing
KMPHARMACEUTICAL Co.,Ltd. belongs to the Banks sector. Filings by its managers are published through DART (FSS). The last twelve months, up to 1 November 2026, brought 42 filings signed by 6 insiders.
Open-market activity splits into 34 purchases totalling €182k and 5 sales; 5 insiders sit on the buying side and 4 insiders on the selling side. The amount is not disclosed for 27 filings. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Biggest ticket of the year: €52k, bought by 강일모 and made public on 11 March 2026 (0.89% of market cap). Among those who bought: 2 board members, 2 chief executives and 1 major shareholder.
Across the 2,655 companies tracked on its exchange, the median is 7 filings; at 42 filings, this issuer sits above that mark. Since 2021, the database holds 52 purchases and 6 sales by insiders of the company.
In all, 9 purchases were made within 30 days of a purchase by another insider of the company. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The latest purchase dates back some time: it was published 54 days ago, on 16 September 2026. Filings reach the DART (FSS) feed a median of 7 days after the trade. The shorter that gap, the sooner other investors can see what insiders have done.
For comparison within the same sector, see the insider buying recorded at BAWAG Group AG and Linc AB. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.
Who traded when
BuySaleSince the insiders bought
- -47.6%Entry ₩1,332 · Close 30 Oct 2026 ₩698
- -73.5%Entry ₩2,635 · Close 30 Oct 2026 ₩698
- -46.4%Entry ₩517 · Close at T+90 ₩277
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- 37,044 sharesShareKRXDART:20260916000178Canonical exit: 15 Dec 2026 (T+90)
- 60,925 sharesShareKRXDART:20260916000177Canonical exit: 15 Dec 2026 (T+90)
- Other0DART
- Other0DART
- 2,849 sharesShareKRXDART:20260730000274Canonical exit: 28 Oct 2026 (T+90)
- Other0DART
- 908,265 sharesShareKRXDART:20260730000222Canonical exit: 28 Oct 2026 (T+90)
- Other0DART
- 1,650 sharesShareKRXDART:20260720000040Canonical exit: 18 Oct 2026 (T+90)
- 1,200 sharesShareKRXDART:20260708000469Canonical exit: 6 Oct 2026 (T+90)
- 1,200 sharesKRXDART:20260708000473Canonical exit: 6 Oct 2026 (T+90)
- 14,421 sharesShareKRXDART:20260701000195Canonical exit: 29 Sept 2026 (T+90)
- 14,421 sharesKRXDART:20260701000201Canonical exit: 29 Sept 2026 (T+90)
- 1,490 sharesKRXDART:20260622000045Canonical exit: 20 Sept 2026 (T+90)
- 1,490 sharesShareKRXDART:20260622000040Canonical exit: 20 Sept 2026 (T+90)
- 8,772,604 sharesKRXDART:20260611000369
- 3,311 sharesShareKRXDART:20260610000560
- 2,344 sharesShareKRXDART:20260610000350
- 373,936 sharesShareKRXDART:20260610000276
- 3,148 sharesShareKRXDART:20260601000849Canonical exit: 17 Aug 2026 (T+90)
- 8,392,209 sharesShareKRXDART:20260601000812
- 11,300 shares0.29% mcap28.2% of flowKRXDART:20260421000240Canonical exit: 12 Jul 2026 (T+90)
- 10,000 shares@ ₩519.51590.051% mcap22.8% of flowShareKRXDART:20260421000222Canonical exit: 14 Jul 2026 (T+90)
- 1,300 shares@ ₩535.06920.0069% mcap100.0% of flowShareKRXDART:20260420000241Canonical exit: 12 Jul 2026 (T+90)
25 of 76 declarations
About KMPHARMACEUTICAL Co.,Ltd.
케이엠제약 is a company operating in the finance and banking sector, listed on the XKRX market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
